Valeant's Overdue SEC Filing Answers Some Big Questions, But Raises New Concerns |
| April 30, 2016 | April 2016 Bond Updates |
|
Valeant's 10-K filing may usher in a process of recovery after months of turmoil, but it also gives new insight into extent of the drugmaker's woes stemming from operational weaknesses, poor disclosure, and regulatory investigations. |
| View more at: http://www.forbes.com/sites/antoinegara/2016/04/29/valeants-overdue-sec-filing-answers-some-big-questions-but-raises-new-concerns/ |